Shots:

• The P-III (FINEARTS-HF) trial assesses the safey & efficacy of finerenone (Kerendia) vs PBO to prevent cardiovascular death & heart failure (HF) events in patients (n=6000) with symptomatic heart failure & LVEF ≥40% for 42mos.
• Study reached its 1EPs, demonstrating reduction in the composite of cardiovascular death and total (first and recurrent) HF events (hospitalizations or urgent HF visits). Finerenone was well-tolerated & aligned with its known safety profile
• The data will be highlighted at ESC 2024 and will be discussed with the US FDA, seeking approval for the drug